# EDGAR Filing Document

**Accession Number:** 0001170316
**File Stem:** 0001170316-23-000002
**Filing Date:** 2023-2
**Character Count:** 5038
**Document Hash:** c3ba4fe96d2aa239c2ace3c3f998d2f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001170316-23-000002.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001170316-23-000002

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verve Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 824800132
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92605
- **FILM NUMBER:** 23624220

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (978) 501-3026

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SINGER JAMES  R
- **CENTRAL INDEX KEY:** 0001170316

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**MAIL ADDRESS:**
- **STREET 1:** PO BOX 1395
- **CITY:** YARMOUTH
- **STATE:** ME
- **ZIP:** 04096

```

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

VERVE THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

92539P101

(CUSIP Number)

DECEMBER 31, 2022

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

[ ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

CUSIP No.  92539P101

1  NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
   (ENTITIES ONLY):

	James R. Singer

2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

	(a) [ ]
	(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America

NUMBER OF  		5  SOLE VOTING POWER 5,000,000
SHARES
BENEFICIALLY  	6  SHARED VOTING POWER None
OWNED BY
EACH REPORTING  	7  SOLE DISPOSITIVE POWER 5,000,000
PERSON WITH:
 			8  SHARED DISPOSITIVE POWER None

9 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

   	5,000,000

10  	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
    	SHARES (see instructions)

	[ ]

11  	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	8.1%

12  	TYPE OF REPORTING PERSON (see instructions)

	IN

Item 1(a).  	Name of Issuer:

		VERVE THERAPEUTICS INC

Item 1(b).  	Address of Issuer's Principal Executive Offices:

 		500 Technology Square, Suite 901
 		Cambridge, MA 02139
   		US

Item 2(a).  	Name of Person Filing:

		The person filing this report is James R. Singer.

Item 2(b).  	Address of Principal Business Office or, if none, Residence:

		PO Box 1395, Yarmouth, ME 04096

Item 2(c).  	Citizenship:

		United States of America

Item 2(d).  	Title of Class of Securities:

		Common Stock

Item 2(e).  	CUSIP Number:  92539P101

Item 3. 	Statements filed pursuant to rules 13D-1(b) or 13D-2(B) or (C)

		Not applicable

Item 4. 	Ownership.

		The information set forth in Rows 5 through 9 and 11 of the cover pages
		of this Schedule 13G is incorporated herein by reference.

Item 5. 	Ownership of Five Percent or Less of a Class.

		Not applicable.

Item 6. 	Ownership of More Than Five Percent on Behalf of Another Person.

	 	Not applicable.

Item 7. 	Identification and Classification of the Subsidiary Which Acquired the
		Security Being Reported on by the Parent Holding Company.

 	  	Not applicable.

Item 8. 	Certification.

 	 	By signing below I certify that, to the best of my knowledge and belief,
		the securities referred to above were not acquired and are not held
		for the purpose of or with the effect of changing or influencing the
		control of the issuer of the securities and were not acquired and are
		not held in connection with or as a participant in any transaction
		having such purpose or effect, other than activities solely in connection
		with a nomination under 240.14a-11.

SIGNATURE

	After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

February 1, 2023
Date

/S/James R. Singer
Signature

JAMES R. SINGER
Name/Title

```